Small Molecules

29 Apr 2017 Takeda Announces FDA Accelerated Approval of ALUNBRIGTM (brigatinib)
29 Apr 2017 Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Ra
28 Apr 2017 Investigational Cladribine Tablets Data Show Greater Treatment Effect in Relapsing MS Patients at a Higher Risk of Disease Progression
28 Apr 2017 Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)
28 Apr 2017 Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating significant anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options
28 Apr 2017 Sage Therapeutics Announces Initiation of Phase 1 Development and First Dosing of SAGE-718
28 Apr 2017 Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer
28 Apr 2017 Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
28 Apr 2017 Bayer Receives FDA Approval for Stivarga® (regorafenib) for the Second-Line Systemic Treatment of Liver Cancer
27 Apr 2017 Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia
27 Apr 2017 Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness
27 Apr 2017 FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND
26 Apr 2017 Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus
25 Apr 2017 ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids
25 Apr 2017 Q Biomed Announces Licensing Agreement for Development of Drug to Treat Rare Pediatric Disorder
25 Apr 2017 Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Intravitreal Sirolimus (DE-109) in the Treatment of Non-Infectious Uveitis of the Posterior Segment
25 Apr 2017 Tagrisso receives full approval in the EU
25 Apr 2017 New Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy
25 Apr 2017 Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy
25 Apr 2017 Vyome Biosciences Completes Enrollment for Proof of Concept Clinical Study of VB 1953 in Patients with Moderate to Severe Acne
24 Apr 2017 Lipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials
24 Apr 2017 Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals
24 Apr 2017 Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis
24 Apr 2017 Achaogen Unveils Data Highlighting the Effectiveness of Plazomicin Against MDR Gram-Negative Bacteria at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
24 Apr 2017 MOLOGEN AG: Positive Subgroup Results of the Exploratory Phase II IMPULSE Study of Lefitolimod in Extensive-Disease Small-Cell Lung Cancer (SCLC)

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing